Dissemination (Meeting Coverage)

Clonal hematopoiesis of indeterminate potential (CHIP) was related to decreased risk of Alzheimer’s disease (AD) and AD neuropathological changes. Mutated hematopoietic stem cells were detected in the brains of CHIP carriers....

Therapy de-escalation in patients with acute lymphoblastic leukemia (ALL) and a low-risk minimal residual disease (MRD) profile was safe, 10-year follow-up results of the UKALL 2003 trial show. Patients with a high-risk MRD...

A combination treatment of quizartinib plus venetoclax plus decitabine was highly active in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukemia (AML). Patients with RAS/MAPK and FLT3-F691L mutations...

A regimen of cladribine plus low-dose cytarabine plus venetoclax alternated with 5-azacytidine plus venetoclax showed encouraging efficacy in patients with newly diagnosed acute myeloid leukemia (AML). Moreover, the displayed...

A triplet combination of 5-azacitidine, venetoclax, and magrolimab displayed promising response rates in newly diagnosed older, unfit, or TP53-mutated patients with acute myeloid leukemia (AML). Moreover, the phase 1b/2 study...

Treatment with fitusiran prophylaxis led to a lower rate of bleeding events and an improved health-related quality of life in patients with hemophilia A or B with inhibitors. The observed safety profile of fitusiran in phase 3...

JAK2V617F variant allele frequency (VAF) >50% is associated with an increased risk of venous thrombosis in patients with polycythaemia vera (PV). This independent predictor distinguished between patients who were classified...

Significant disparities in health outcomes were observed across race, ethnicity, and socioeconomic status (SES) in patients with acute lymphoblastic leukemia (ALL). Differences in leukemia biology or disease prognosticators do...

The combination therapy of eprenetapopt plus azacytidine showed favorable efficacy and safety in patients with TP53-mutant myelodysplastic syndrome (MDS) and oligoblastic acute myeloid leukemia (AML). Patients with biallelic...

Liposomal daunorubicin/cytarabine (CPX-351) therapy did not result in different overall survival (OS) outcomes or response rates than venetoclax plus HMA therapy in patients with acute myeloid leukemia (AML) between 60 and 75...

The combination regimen of low-dose tacrolimus plus high-dose dexamethasone provides benefits over high-dose dexamethasone monotherapy in patients with immune thrombocytopenia (ITP). Both the initial response rates and the...

Talquetamab plus daratumumab demonstrated durable and deep responses in heavily pre-treated patients with refractory multiple myeloma (MM). Furthermore, the combination regimen was tolerable and did not show overlapping...

Scientific Sessions Programming For Presenters and Moderators Specialty Focused Programming Late-Breaking Science Online Program Planner CME/CE Credit Mobile Meeting Guide Live Sessions Session CH.AOS.463 226 – Impact of...

Source: American Heart Association Scientific Sessions 2021 “One World. Together for Science.” #AHA21 Join the American Heart Association Scientific Sessions 2021 virtual platform for the global cardiovascular event...

To Come…

To Come…

To Come….

This year’s Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, the leading research and educational conference for MS healthcare professionals in North America, kicks off tomorrow, October 25 through October...

 Findings presented at ECTRIMS 2021 suggest that deep, persistent B-cell depletion is linked to reduced disease activity Results from a new analysis of the inebilizumab pivotal Phase 2/3 N-MOmentum trial were presented this year...